Ashley Gallagher, Associate Editor

The drug is currently undergoing a phase 2 clinical trial for patient 12 years or older who are hospitalized with steroid-refractory acute graft-versus-host disease (aGVHD).

The combination is the first and only multi-targeted chemotherapy-free regimen that demonstrated superiority compared with osimertinib for non–small cell lung cancer (NSCLC).

Currently, the drug will be studied in the SKYBRIDGE (NCT05652686) trial, a first-in-human, phase 1/2, open-label, dose-escalation and expansion study.

The biosimilar space continues to grow, with key focuses around retina and oncology, but adoption remains slow in the United States.

The hemostatic gel is plant-based and designed to stop and control bleeding within seconds after applied to wound at the point of care.

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

The treatment is indicated to improve and maintain visual acuity in individuals with neovascular age-related macular degeneration.

Walgreens will close underperforming stores within the next 3 years, struggling to keep up with front-of-store experiences and regulatory and reimbursement challenges.

The trial evaluated a fixed-dose combination of vibostolimab and pembrolizumab in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer.

Palopegteriparatide is a prodrug of parathyroid hormone designed to provide continuous exposure of the hormone over a 24-hour dosing period.

Many patients are unaware of wound complication, so it is valuable for pharmacists to communicate prevention methods with all patients with diabetes.

Investigators find that this could suggest the biosimilar uptake alone may not be a complete measure of the market competition and lowering prices.

Previously, an independent advisory panel for the FDA rejected the use of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), citing concerns of the reliability of the clinical trial data.

neffy is an epinephrine nasal spray for the emergency treatment of allergic reactions in adults and pediatric patients.

Denileukin diftitox-cxdl is the only therapy approved for cutaneous T-cell lymphoma that targets IL-2 receptors in malignant T-cells and Tregs.

Carbidopa and levodopa extended-release capsules are a novel, oral formulation that combine immediate-release granules and extended-release pellets.

The ADA Clinical Practice Recommendations added sleep assessment for precision medicine in type 2 diabetes, supporting the wealth of information surrounding the association.

Sunobinop binds to and activate nociception/orphanin-FQ peptide receptor, which is a known therapeutic target for substance use disorder.

A report from SkyQuest Technology highlights the growth in the oncology and insulin spaces, indicating they will contribute to the most growth.

The drug also receives orphan drug designation for the treatment of pancreatic neuroendocrine tumors and a Prescription Drug User Fee Act target action date of April 3, 2025.

Customers report that their communication is strong with their pharmacists, but only 51% said their pharmacist was trustworthy.

In the first half of 2024, the FDA approved 23 novel drugs for conditions including alopecia areata, Alzheimer disease, small cell lung cancer, bladder cancer, and more.

This is the first and only on-demand, virus-inactivated, human plasma-derived concentration option that is indicated for this approval.

The drug previously received breakthrough therapy designation for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia that is in chronic phase.

The system is an outpatient procedure that resurfaces the mucosal lining, making it easier for the body to maintain healthy metabolism and blood glucose levels.

The designation is based on animal model studies that have demonstrated superior efficacy in comparison to sildenafil.

If approved, the drug would be the first in a new class of medications to treat acute pain in over 20 years.

The approval marks the first oral immunotherapy treatment to mitigate allergic reactions, including anaphylaxis.

Paliperidone palmitate (Erzofi; Luye Pharma Group) is approved as a monotherapy for schizophrenia and as an adjunct for schizoaffective disorder.

The similarities were shown for both the US formulation and the EU formulation.